micro dose of glp 1 What Is Microdosing GLP-1s, and Is It Safe? Microdosing GLP-1s

Between 2025 and 2030, the global pharmaceutical industry faces a Loss of Exclusivity (LOE) wave that puts an estimated $200 billion to $400 billion in branded drug revenue at direct risk.

Part II: The Gray Market of Compounded GLP-1 Injections A Dangerous Alternative The sterile compounding pharmacy you choose is important

Featuring 500 million AFUs of Akkermansia muciniphila, Clostridium butyricum, and Bifidobacterium infantis with chicory inulin for gut support

Doctors break it all down.

Biopharma bigwigs Eli Lilly and Novo Nordisk are upping capacity to meet the rising demands of GLP-1 drugs.

This acceleration coincided with surging demand for semaglutide and tirzepatide, two therapies that have become synonymous with the new era of diabetes and obesity treatment